United Therapeutics Corporation has published full results of the TETON-2 phase 3 trial in The New England Journal of Medicine, showing that nebulized treprostinil (Tyvaso) significantly slowed lung function decline in patients with idiopathic pulmonary fibrosis over 52 weeks. The inhaled prostacyclin mimetic achieved its primary endpoint of absolute forced vital capacity change, with a between-group difference of 95.6 mL versus placebo, and also reduced the risk of clinical worsening events by 29 percent. The company has announced plans to file a supplemental New Drug Application with the FDA by the second half of 2026, pending results from the companion TETON-1 study.

Why this endpoint matters more than the numbers suggest

The FVC result deserves careful framing. IPF is characterised by relentless, progressive scarring of lung tissue, and the standard of care has historically centred on oral antifibrotics, nintedanib and pirfenidone, which slow but do not halt disease progression. The median absolute FVC decline in the placebo arm of TETON-2 was 136.4 mL over 52 weeks, a figure broadly consistent with natural history data and placebo arms in prior antifibrotic trials. The treprostinil group declined by 49.9 mL. The 95.6 mL between-group difference is not a trivial margin in a disease where even modest FVC preservation correlates meaningfully with survival and transplant eligibility.

Critically, 75 percent of enrolled patients were already on background antifibrotic therapy, either nintedanib or pirfenidone. The benefit of nebulized treprostinil was observed across all subgroups regardless of background therapy use, smoking status, or supplemental oxygen dependence. That finding, if confirmed in TETON-1, substantially strengthens the case for treprostinil as an add-on therapy rather than an alternative, positioning it to occupy a distinct and potentially additive therapeutic lane. Industry observers note that demonstrating benefit on top of established antifibrotics is a more commercially and clinically demanding bar than a head-to-head comparison with placebo alone, which makes the TETON-2 result more persuasive than a similarly-sized benefit observed in a treatment-naive population.

The inhaled route as a mechanism differentiator

The study authors described TETON-2 as the first trial to demonstrate that an inhaled therapy slowed fibrosis progression as assessed by FVC change in IPF patients. That characterisation is significant beyond marketing. The inhaled route achieves high local drug concentrations in the lung parenchyma while limiting systemic exposure, a pharmacokinetic advantage that is particularly relevant in a disease where the target tissue is the lung itself. Oral and injectable prostacyclin therapies have well-established roles in pulmonary arterial hypertension, but their systemic vasodilatory profiles have historically complicated use in a predominantly older, predominantly male IPF population with a high burden of comorbidities.

The tolerability data from TETON-2 appear to support the inhaled route’s advantage. The most frequent adverse events were cough, headache, and diarrhoea, all of which are consistent with prior Tyvaso studies and known prostacyclin class effects. No new safety signals were reported, and the company characterised the profile as well-tolerated. Clinicians tracking the field note that cough is already endemic in IPF, which may complicate patient and physician attribution of adverse events in real-world use, but does not inherently limit the drug’s utility if the cough burden is manageable.

What the DLCO and K-BILD results add to the picture

Beyond FVC, TETON-2 reported statistically significant improvements in the diffusion capacity of the lungs for carbon monoxide (DLCO) and in the King’s Brief Interstitial Lung Disease quality of life questionnaire (K-BILD). DLCO measures the lung’s ability to transfer gas into the bloodstream, a function that deteriorates as fibrosis advances. Improvements in DLCO alongside FVC suggest a broader physiological benefit than slowed air movement alone, pointing to potential preservation of alveolar-capillary interface function. The K-BILD signal adds a patient-centred dimension that regulators and payers have increasingly required as corroborating evidence in pulmonary trials.

Taken together, the multi-domain improvement across FVC, clinical worsening, DLCO, and quality of life is the strongest evidentiary configuration the company could have hoped for. A trial that moved the primary endpoint but missed most secondaries would have raised durability questions. The breadth of improvement across mechanistically distinct outcomes makes a more coherent case for regulatory approval and commercial adoption.

Regulatory pathway and timeline risks

The planned sNDA submission to the FDA is contingent on TETON-1 data, which are described as expected soon. TETON-1 enrolled patients in the United States and Canada, while TETON-2 enrolled internationally across sixteen countries including Argentina, Australia, Germany, South Korea, Spain, and Taiwan. The geographic split was likely a pragmatic clinical development decision, but it means the FDA submission will rest primarily on TETON-1 as the pivotal US registration study, with TETON-2 providing supporting evidence. If TETON-1 misses its primary endpoint or shows a materially smaller effect size, the regulatory path becomes substantially more complicated despite the TETON-2 publication.

Both the FDA and the European Medicines Agency have already granted orphan designation for treprostinil in IPF, which confers seven-year market exclusivity in the United States and ten years in Europe following approval, along with expedited regulatory interactions. Regulatory watchers suggest orphan designation does not guarantee approval but does signal that both agencies view IPF as an unmet medical need and have agreed that treprostinil’s mechanism is plausibly relevant to the disease. The second-half 2026 submission timeline leaves limited room for TETON-1 delays or data queries without pushing a likely approval decision into 2027 or beyond.

Commercial dynamics and the antifibrotic landscape

If approved, nebulized treprostinil would enter an IPF market currently dominated by two oral antifibrotics: nintedanib, marketed by Boehringer Ingelheim as Ofev, and pirfenidone, sold by Roche under the Esbriet brand in some markets. Both agents have well-established safety and efficacy profiles, significant commercial infrastructure, and entrenched prescriber familiarity. The TETON-2 population’s high background antifibrotic use was both a trial design strength and a commercial signal: patients and physicians are already comfortable with combination pharmacological management, which lowers the adoption barrier for an add-on inhaled therapy.

Nebulized drug delivery carries its own set of commercial challenges. Patient adherence to inhaled regimens requiring multiple daily sessions is consistently lower in real-world use than in clinical trials, particularly in a population with a median age of 71.7 years and significant comorbid burden. The TD-300 TYVASO Inhalation System requires patient training and ongoing device management, which adds complexity relative to oral dosing. Payer willingness to reimburse a second-line or add-on inhaled therapy at probable specialty drug pricing will depend heavily on the durability of the FVC and quality-of-life data, as well as any health economic modelling United Therapeutics presents alongside the sNDA.

What TETON PPF and the open-label extension reveal about the broader strategy

United Therapeutics is running a third arm of the TETON programme, TETON PPF, evaluating nebulized treprostinil in progressive pulmonary fibrosis, a heterogeneous category that includes non-IPF fibrotic interstitial lung diseases such as fibrotic hypersensitivity pneumonitis and autoimmune-associated ILD. Enrollment in TETON PPF is ongoing. The company’s strategy appears to be establishing treprostinil as a platform inhaled antifibrotic therapy across the fibrotic ILD spectrum, rather than limiting the asset to the narrower IPF indication. If TETON PPF succeeds, the addressable patient population expands considerably beyond the estimated 100,000 IPF patients in the United States.

Eligible TETON-2 completers could enrol in the TETON open-label extension study, which is evaluating long-term safety and tolerability in fibrotic lung disease. Long-term extension data will be critical for supporting real-world use, given that IPF is a chronic progressive disease and clinicians will want reassurance that the FVC benefit is sustained beyond 52 weeks and that the safety profile does not deteriorate with cumulative exposure. Those data will likely arrive too late to influence the initial sNDA review but will be essential for post-approval market positioning and guideline uptake.

The unresolved questions clinicians will watch

Several meaningful questions remain unanswered by TETON-2 in isolation. The 52-week trial duration, while standard for IPF regulatory submissions, does not capture the disease’s full natural history or the therapy’s long-term durability. The absolute FVC difference of 95.6 mL is statistically robust but clinicians have debated the minimum clinically important difference in FVC for IPF, with some thresholds cited in the literature above 100 mL. The study population had a mean baseline percent predicted FVC of 76.8 percent, representing mild to moderate disease; whether the benefit extends to patients with more advanced fibrosis or those with concurrent pulmonary hypertension remains an open question, particularly given treprostinil’s established role in pulmonary hypertension associated with ILD.

The published results represent one of the more compelling phase 3 readouts in IPF in recent years, but the field has been here before: trials that generated initial enthusiasm have been followed by approval pathways complicated by regulatory requests, inconsistent TETON-1 results, or payer access barriers. Until TETON-1 data are in hand and an FDA advisory committee has assessed the full benefit-risk profile, the commercial and clinical inflection point remains contingent.

  antifibrotic therapy, clinical worsening, DLCO, FDA, forced vital capacity, FVC, idiopathic pulmonary fibrosis, ILD, inhaled therapy, interstitial lung disease, IPF, lung disease, NEJM, New England Journal of Medicine, nintedanib, orphan drug, Phase 3 trial, pirfenidone, prostacyclin, pulmonary fibrosis, pulmonary hypertension, respiratory disease, supplemental NDA, TETON-2, treprostinil, Tyvaso, United Therapeutics